PHAT Projected Dividend Yield
Phathom Pharmaceuticals Inc ( NASDAQ : PHAT )Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Co.'s primary product candidate, vonoprazan, is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has shown effects and has demonstrated clinical results as an agent in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of H. pylori infection. 20 YEAR PERFORMANCE RESULTS |
PHAT Dividend History Detail PHAT Dividend News PHAT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |